Peter Bartenstein
Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.
Overview
Peter Bartenstein is Director of the Department of Nuclear Medicine at LMU Klinikum München. His specialisms are nuclear medicine, PSMA theranostics and neuro-imaging. His department is a leading European centre for PSMA PET and lutetium-177 PSMA radioligand therapy, and it co-developed 177Lu-PSMA-I&T. His papers include a dosimetry study of 177Lu-DKFZ-PSMA-617 as a new radiopharmaceutical for metastatic prostate cancer, the first clinical results of 18F-SiFAlin-TATE PET for imaging neuroendocrine tumours, and a European Urology study showing that 68Ga-PSMA PET/CT accurately stages lymph node regions before dissection in prostate cancer. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2015 |
| Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors | European Journal of Nuclear Medicine and Molecular Imaging | 2019 |
| 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer | European Urology | 2016 |
Similar pages
not linked directly; found by shared links- PersonJeremie Calais
Shares PSMA, PSMA PET, Fluorine-18, Gallium-68.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- AgentFlotufolastat F-18
Shares PSMA, PSMA PET, Fluorine-18, Gallium-68.
- CompanyBracco Imaging
Shares PSMA, PSMA PET, Fluorine-18, Prostate cancer.
- PersonThomas A. Hope
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- IdeaBispecific PSMA/GRPR radioligands for discordant prostate cancer lesions
Shares PSMA, PSMA PET, Gallium-68, Lutetium-177.
- AgentPSMA-1007 F-18
Shares PSMA, PSMA PET, Fluorine-18, Gallium-68.